{"id":230999,"date":"2026-02-10T05:03:16","date_gmt":"2026-02-10T11:03:16","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/02\/current-future-role-of-anktiva-n-803-dr-patrick-soon-shiong"},"modified":"2026-02-10T05:03:16","modified_gmt":"2026-02-10T11:03:16","slug":"current-future-role-of-anktiva-n-803-dr-patrick-soon-shiong","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/02\/current-future-role-of-anktiva-n-803-dr-patrick-soon-shiong","title":{"rendered":"Current &amp; Future Role of Anktiva (N-803): Dr. Patrick Soon-Shiong"},"content":{"rendered":"<p><\/p>\n<p><iframe style=\"display: block; margin: 0 auto; width: 100%; aspect-ratio: 4\/3; object-fit: contain;\" src=\"https:\/\/www.youtube.com\/embed\/aRDyqswYUOY?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; encrypted-media; gyroscope;\n   picture-in-picture\" allowfullscreen><\/iframe><\/p>\n<p>In this episode of the Oncology Brothers podcast, we engaged in a thought-provoking discussion with Dr. Patrick Soon-Shiong, a pioneer in oncology and the innovator behind the approval of nab-paclitaxel (Abraxane). We delved into the exciting potential of Anktiva (N-803), an IL-15 receptor super agonist designed to expand and activate natural killer (NK) cells and CD8 T cells, with the hope of revolutionizing cancer treatment.<\/p>\n<p>Dr. Soon-Shiong shared insights into the mechanism of action of Anktiva, its current approvals in non-muscle invasive bladder cancer, and extended approval in non-small cell lung cancer in Saudi Arabia, and the promising clinical trial data that suggests a significant increase in overall survival for patients. The conversation also touched on the importance of restoring lymphocyte counts and the implications for treating various tumor types.<\/p>\n<p>Join us as we explore the future of immunotherapy, the challenges of regulatory approval, and the potential for Anktiva to change the landscape of cancer treatment.<br \/> Key Topics:<br \/> \u2022 Mechanism of action of Anktiva.<br \/> \u2022 Current approvals and clinical trial data.<br \/> \u2022 The role of lymphocyte counts in cancer treatment.<br \/> \u2022 Future directions for immunotherapy.<\/p>\n<p>Follow us on social media:<br \/> \u2022 \u2060 \u2060X\/Twitter: \/ oncbrothers.<br \/> \u2022 \u2060 \u2060Instagram: \/ oncbrothers.<br \/> \u2022 \u2060 Website: <a href=\"https:\/\/oncbrothers.com\/\">https:\/\/oncbrothers.com\/<\/a><\/p>\n<p>Don\u2019t forget to like, subscribe, and hit the notification bell for more discussions on the latest in oncology!<\/p>\n<p>#Oncology #CancerTreatment #Immunotherapy #IL15Agonist #OncologyBrothers<\/p>\n<div class=\"more-link-wrapper\"> <a class=\"more-link\" href=\"https:\/\/lifeboat.com\/blog\/2026\/02\/current-future-role-of-anktiva-n-803-dr-patrick-soon-shiong\">Continue reading \u201cCurrent &amp; Future Role of Anktiva (N-803): Dr. Patrick Soon-Shiong\u201d | &gt;<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>In this episode of the Oncology Brothers podcast, we engaged in a thought-provoking discussion with Dr. Patrick Soon-Shiong, a pioneer in oncology and the innovator behind the approval of nab-paclitaxel (Abraxane). We delved into the exciting potential of Anktiva (N-803), an IL-15 receptor super agonist designed to expand and activate natural killer (NK) cells and [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,20],"tags":[],"class_list":["post-230999","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-futurism"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/230999","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=230999"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/230999\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=230999"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=230999"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=230999"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}